Company Insights

SOPH customer relationships

Explore interactive graphBrowse insights index
SOPH customer relationship map

SOPH (Sophia Genetics) — Customer Relationships and What They Signal to Investors

Sophia Genetics operates an AI-driven clinical genomics platform (SOPHiA DDM) that monetizes through recurring software and application licenses, clinical test enablement, and strategic co-development with biopharma and diagnostics partners; revenue growth is driven by new customer acquisition plus expansion of applications inside existing accounts. For investors, the relevant takeaway is simple: growth is product-led and expansion-driven, with strategic commercial deals (pharma and large labs) acting as accelerants to clinical adoption and regulated diagnostic pathways.
If you want a structured signals product that tracks these customer dynamics, visit https://nullexposure.com/ for more.

What the customer roll-up reveals about SOPH's operating model

Sophia’s customer activity in FY2025–FY2026 shows a repeatable commercial motion: enterprise wins at academic medical centers and national labs, plus partnerships with pharma and diagnostics companies that convert platform deployments into regulated or co-developed offerings. That pattern implies:

  • Contracting posture: a mix of SaaS-style platform agreements and commercial collaborations; pharma deals (e.g., with Myriad, AstraZeneca) point to multi-year, higher-touch arrangements rather than one-off purchases.
  • Concentration and criticality: adoption by major cancer centers and national institutes signals high clinical criticality for oncology and rare-disease workflows, reducing churn risk for deeply embedded customers while increasing exposure to long sales cycles.
  • Maturity and expansion runway: frequent “add-on application” announcements (MSK-ACCESS, MSK-IMPACT Flex, solid tumor modules) indicate a land-and-expand model where initial clinical use cases seed follow-on revenue.
  • Geographic diversification: new wins across North America, Europe, LATAM, APAC reflect international distribution that mitigates single-market risk but increases regulatory and implementation complexity.

For a deeper look at how these relationships move revenue and risk, see https://nullexposure.com/.

Customer roll-up: each named relationship and source notes

Below are every customer relationship referenced in the FY2025–FY2026 reporting set, each with a succinct statement and the primary source.

  • AstraZeneca — Renewed global commercial agreement and sponsor of MSK Access deployment, underscoring a strategic pharma partnership to scale a liquid-biopsy offering. Source: Q4 2025 earnings call transcript (InsiderMonkey) and earnings coverage (The Globe and Mail), March 2026 — https://www.insidermonkey.com/blog/... and https://www.theglobeandmail.com/...

  • AZ Delta / AZ Delta system — Signed as a new regional system customer in Belgium for SOPHiA applications, part of Q4 customer wins. Source: PR Newswire Q4 2025 release, March 2026 — https://www.prnewswire.com/...

  • Citogen — Signed to SOPHiA’s solid tumor application in Spain, reflecting expansion into private pathology labs. Source: Q4 2025 earnings call transcript (InsiderMonkey), March 2026 — https://www.insidermonkey.com/...

  • Human Genome and Stem Cell Research Center (Brazil) — New Latin American customer for SOPHiA solutions, evidencing growth in Brazil. Source: Q4 2025 earnings release (PR Newswire) and transcript coverage, March 2026 — https://www.prnewswire.com/... and https://www.theglobeandmail.com/...

  • Icahn School of Medicine at Mount Sinai — Expanded footprint by adopting additional SOPHiA applications including MSK-ACCESS, demonstrating upsell at a major academic center. Source: Q4 2025 earnings release (PR Newswire) and call transcript coverage, March 2026 — https://www.prnewswire.com/... and https://www.insidermonkey.com/...

  • Labpoint Medical Lab — Signed to SOPHiA’s application in Switzerland, a targeted lab-level win in Europe. Source: Q4 2025 earnings call transcript (InsiderMonkey), March 2026 — https://www.insidermonkey.com/...

  • Memorial Healthcare System (Florida) — Adding MSK-ACCESS as an expansion in South Florida, an example of regional health system adoption. Source: Q4 2025 earnings call transcript and PR release, March 2026 — https://www.insidermonkey.com/... and https://www.prnewswire.com/...

  • National Institute of Genomic Medicine (Mexico) — Signed for the MSK-ACCESS liquid biopsy application, marking a public-institute adoption in Latin America. Source: Q4 2025 PR Newswire and call transcript, March 2026 — https://www.prnewswire.com/... and https://www.insidermonkey.com/...

  • National Taiwan University Hospital — Adopted multiple SOPHiA applications for solid tumor testing, reflecting APAC institutional traction. Source: Q4 2025 earnings call transcript (InsiderMonkey), March 2026 — https://www.insidermonkey.com/...

  • NYU Langone Health — Recorded as a new Q4 customer in the U.S., broadening SOPHiA’s presence among major U.S. academic centers. Source: Q4 2025 PR Newswire, March 2026 — https://www.prnewswire.com/...

  • Ospedale di Circolo e Fondazione Macchi (Italy) — Signed MSK-IMPACT Flex for solid tumor testing, an Italian hospital-level win. Source: Q4 2025 earnings call transcript (InsiderMonkey), March 2026 — https://www.insidermonkey.com/...

  • Parapath (Austria) — Signed for MSK-IMPACT Flex, indicating penetration into Austria’s pathology market. Source: Q4 2025 earnings call transcript (InsiderMonkey), March 2026 — https://www.insidermonkey.com/...

  • Peter MacCallum Cancer Centre (Australia) — Expanded SOPHiA footprint at a leading Australian cancer center, signaling deeper enterprise engagement. Source: Q4 2025 earnings call transcript (InsiderMonkey/The Globe and Mail), March 2026 — https://www.insidermonkey.com/... and https://www.theglobeandmail.com/...

  • Protlab (Florida) — New customer win in the U.S. clinical lab sector, part of Q4 additions. Source: Q4 2025 earnings call transcript (InsiderMonkey), March 2026 — https://www.insidermonkey.com/...

  • Royal Infirmary of Edinburgh — Signed MSK-ACCESS as part of over 70 customers to the liquid biopsy application, expanding UK presence. Source: Q4 2025 call transcript and PR release, March 2026 — https://www.insidermonkey.com/... and https://www.prnewswire.com/...

  • Vanderbilt University School of Medicine — Adopted additional SOPHiA applications (expand motion), another upsell example in North America. Source: Q4 2025 earnings call transcript (InsiderMonkey), March 2026 — https://www.insidermonkey.com/...

  • Carlos Chagas Institute (Brazil) — Signed SOPHiA DDM for HemOnc testing, reinforcing Brazilian momentum. Source: Q4 2025 earnings transcript coverage (The Globe and Mail), March 2026 — https://www.theglobeandmail.com/...

  • RareCyte Inc. — Implemented SOPHiA DDM to complement its precision biology services, highlighting an industry partner integration (FY2024 announcement). Source: Seeking Alpha / PR coverage (FY2024) — https://seekingalpha.com/pr/...

  • Baylor Scott & White Health — Adoption of SOPHiA DDM for HemOnc at a large Texas health system, another anchor account in the U.S. Source: Q4 2025 earnings coverage (The Globe and Mail/PR), March 2026 — https://www.theglobeandmail.com/... and https://www.prnewswire.com/...

  • The University of Texas MD Anderson Cancer Center — Strategic collaboration to use SOPHiA AI tech for RNA-seq bioinformatics pipelines, indicating research-to-clinical co-development potential. Source: Finviz report on partnership (FY2026) — https://finviz.com/news/...

  • Geisinger Health System — Adopted SOPHiA DDM for pharmacogenomics, showing diversification into PGx use cases. Source: Q4 2025 earnings transcript coverage (The Globe and Mail), March 2026 — https://www.theglobeandmail.com/...

  • Gustave Roussy (Paris) — Adding new solid tumor applications to its existing SOPHiA suite, an expansion within an established customer. Source: Q4 2025 earnings transcript coverage (The Globe and Mail), March 2026 — https://www.theglobeandmail.com/...

  • Myriad Genetics — Partnership to develop MSK Access into a regulated companion diagnostic in the U.S., converting platform IP into a regulated offering. Source: Q4 2025 earnings transcript coverage (The Globe and Mail), March 2026 — https://www.theglobeandmail.com/...

  • Sunnybrook Health Sciences Centre — Adding MSK Access as an additional clinical data management application, expanding Canadian footprint. Source: Q4 2025 earnings transcript coverage (The Globe and Mail), March 2026 — https://www.theglobeandmail.com/...

  • Tulane University — Adding new solid tumor applications, reflecting further U.S. academic penetration. Source: Q4 2025 earnings transcript coverage (The Globe and Mail), March 2026 — https://www.theglobeandmail.com/...

  • Tyrolpath (Austria) — Named among Q4 new customers and one of Austria’s larger pathology labs, demonstrating market share gains in Austria. Source: Q4 2025 PR Newswire, March 2026 — https://www.prnewswire.com/...

  • Vitalité Health Network (Canada) — Signed MSK-ACCESS as part of liquid biopsy customer roll-out, expanding into Canadian health networks. Source: Q4 2025 PR Newswire, March 2026 — https://www.prnewswire.com/...

  • ADAM Innovations / A.D.A.M. Innovations — Partnering to bring SOPHiA DDM to Japan and implement the full suite including liquid biopsy, an international distribution partner arrangement (FY2025–FY2026). Source: MarketScreener and Globe coverage (FY2025–FY2026) — https://www.marketscreener.com/... and https://www.theglobeandmail.com/...

  • American University of Beirut — Signed MSK Impact Flex for solid tumor testing, an institutional expansion in the Middle East. Source: Q4 2025 earnings transcript coverage (The Globe and Mail), March 2026 — https://www.theglobeandmail.com/...

  • Thermo Fisher Life Labs — Adopting solid tumor, liquid biopsy and rare disorders applications, a commercial partnership with a major lab-services brand. Source: Q4 2025 earnings transcript coverage (The Globe and Mail), March 2026 — https://www.theglobeandmail.com/...

  • New South Wales Pathology — Adding applications in Australia, indicating public pathology engagement at scale. Source: Q4 2025 earnings transcript coverage (The Globe and Mail), March 2026 — https://www.theglobeandmail.com/...

  • University Hospital of Nice — Signed in Q3 for SOPHiA applications, expanding French hospital customer base. Source: Q4 2025 earnings transcript coverage (The Globe and Mail), March 2026 — https://www.theglobeandmail.com/...

  • ClinicaMeds (Chile) — Signed to whole exome solution in Latin America, an example of clinical genomics adoption in Chile. Source: Q4 2025 earnings transcript coverage (The Globe and Mail), March 2026 — https://www.theglobeandmail.com/...

  • GESA — Cited as a major recent win contributing to Belgium and Germany growth, supporting regional revenue acceleration. Source: Q4 2025 earnings call transcript (InsiderMonkey), March 2026 — https://www.insidermonkey.com/...

  • HSL (UK) — Signed in Q3 alongside other European hospitals, part of UK expansion. Source: Q4 2025 earnings transcript coverage (The Globe and Mail), March 2026 — https://www.theglobeandmail.com/...

(Each entry above is drawn from the company’s Q4 2025 reporting and related press coverage consolidated in March 2026; URLs point to the original coverage included in Sophia’s public disclosures.)

Constraints and company-level signals for investors

No customer-specific contractual constraints were provided in the referenced material; company-level signals from the customer roll-up are: land-and-expand commercial model, mix of regulated-product pathways via pharma/diagnostic partners, geographically diversified sales, and high clinical stickiness driven by academic and national institute adoption. Those signals imply a balance of steady recurring revenue with elevated execution risk around regulatory conversions and multi-year commercial integrations.

Bottom line and investor action items

Sophia’s FY2025–FY2026 customer activity shows clear expansion inside elite academic centers and concrete pharma/diagnostics partnerships that convert platform placements into regulated or co-developed products, which materially strengthens monetization pathways if execution continues. For investors and operators tracking adoption signals or building exposure to clinical AI platforms, review the customer list above and monitor progress on companion-diagnostic conversions and regulated product launches. Explore our coverage and tracking tools at https://nullexposure.com/ for ongoing updates and portfolio signals.